KTTA Stock — Pasithea Therapeutics Corp.: Cash, EV, Pipeline

What they do

We are a clinical-stage biotechnology company focused on the discovery, research and development of innovative treatments for RASopathies, MAPK pathway-driven tumors, and other diseases, including central nervous system (CNS) disorders.

Source: 10-K FY2025 via SEC EDGAR

Share price

$0.58

Market cap

$19.3M

Cash

$45.7M

Enterprise value

-$26.4M

Balance sheet

Cash	$45.7M
Debt	$0.0M
Net cash	$45.7M
Enterprise value	-$26.4M
Basic shares	33.4M shares
Fully diluted shares	107.7M shares
Fully diluted market cap	$62.5M
Cash per share	$1.37
Quarterly burn	$4.7M
Cash runway	9.7 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

33.4M

Pre-funded warrants

54.8M

Options

7.6M

RSUs

0.0M

Warrants

11.9M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.0M

FDSO

107.7M

Cap table as of 2026-06-30.

Price history

Loading KTTA daily closes…

Loading price history…

Next catalyst

PAS-004 Tablets · Oct 13 - Nov 24 in 11 mo · Phase 1 · NF1 Mutation; Neurofibroma Plexiform; Neurofibroma, Plexiform

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Oct 13 - Nov 24 in 11 mo	PAS-004 Tablets	Phase 1	NF1 Mutation; Neurofibroma Plexiform; Neurofibroma, Plexiform	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

PAS-004

Phase 1 · Active Modality: small molecule (macrocyclic, oral)

Target MEK

Partnerships ALS Association ($1M Hoffman Clinical Trial Awards Program award, Nov 2025, for investigator-initiated trial of PAS-004 in ALS; terms being negotiated)

Indications

NF1 plexiform neurofibromas (adult) (Phase 1)
MAPK pathway-driven advanced solid tumors (Phase 1)
NF1 plexiform neurofibromas (pediatric) (Stage not disclosed)

Catalysts

— None
— None

Status note Next-generation oral once-daily macrocyclic MEK inhibitor for long-term treatment of chronic diseases including NF1. First-in-human Phase 1 Advanced Cancer Study ongoing. Phase 1/1b Adult NF1 trial initiated May 2025, first patient dosed late July 2025. Pediatric NF1-PN Phase 1 and registrational trials in adult and pediatric populations planned.

PAS-001

Discovery · Active

Target C4A

Indications

Schizophrenia (Discovery)

Status note Discovery-stage program for the treatment of schizophrenia.

PAS-003

Stage not disclosed · Terminated

Indications

Amyotrophic lateral sclerosis (ALS) (Stage not disclosed)

Status note Company determined to cease further development of the PAS-003 program for ALS during the year ended Dec 31, 2025, citing significant capital, resources and time required to develop the program.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	PAS-004 Capsules
Lead indication	RAS Mutation
Lead phase	Phase 1
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06961565	Phase 1	Recruiting	Sponsor	KTTA	—	NF1 Mutation; Neurofibroma Plexiform; Neurofibroma, Plexiform	—
NCT06299839	Phase 1	Recruiting	Sponsor	KTTA	—	RAS Mutation; NF1 Mutation; RAF Mutation	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Pasithea Therapeutics Corp. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Stonepine Capital	2,201,468	+1,370,167	0.86%	2026-08-17
Vivo Capital	465,471	-1,634,529	0.02%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

KTTA — Pasithea Therapeutics Corp. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

KTTA — Pasithea Therapeutics Corp.